Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
NCT07089576 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of the ascending aorta.
Conditions Studied
Interventions
- DEVICE Arcevo™ LSA Hybrid Stent Graft System
Study Locations (10)
New York
- Columbia University Irving Medical Center/New York Presbyterian Hospital — New York
- Montefiore Medical Center — The Bronx
Texas
- University of Texas - Austin — Austin
- Baylor Scott & White — Plano
California
- University of Southern California — Los Angeles
Georgia
- Emory University School of Medicine — Atlanta
Illinois
- Northwestern University Feinberg School of Medicine — Chicago
Maryland
- Johns Hopkins Hospital — Baltimore
Ohio
- Cleveland Clinic Foundation — Cleveland
Wisconsin
- Medical College of Wisconsin — Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2032-07 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07089576
The ClinicalTrials.gov registry entry for NCT07089576 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Artivion, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Aortic Arch Aneurysm appearing as the primary indexed condition, and to 1 intervention — of which Arcevo™ LSA Hybrid Stent Graft System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07089576 reports 10 study locations spanning 8 distinct geographic areas — top geographies include New York, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07089576 about?
NCT07089576 is a clinical study titled "Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA". The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of the ascending aorta.
What is the current status of trial NCT07089576?
This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2025-11-04. Estimated completion is 2032-07.
What conditions does trial NCT07089576 study?
This clinical trial studies the following conditions: Aortic Arch Aneurysm, Aortic Arch Dissection, Acute Aortic Dissection, Chronic Aortic Dissection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07089576?
The interventions under investigation include: Arcevo™ LSA Hybrid Stent Graft System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07089576?
This trial is sponsored by Artivion, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07089576 being conducted?
This trial has 10 study locations across California, Georgia, Illinois, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.